Theradiag (France) Performance
| ALTHE Stock | EUR 0.25 0.01 4.17% |
The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Theradiag's returns are expected to increase less than the market. However, during the bear market, the loss of holding Theradiag is expected to be smaller as well. At this point, Theradiag SA has a negative expected return of -0.48%. Please make sure to validate Theradiag's potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if Theradiag SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Theradiag SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 2.3 M | |
| Total Cashflows From Investing Activities | -524.5 K | |
| Free Cash Flow | -4 M |
Theradiag |
Theradiag Relative Risk vs. Return Landscape
If you would invest 38.00 in Theradiag SA on November 9, 2024 and sell it today you would lose (13.00) from holding Theradiag SA or give up 34.21% of portfolio value over 90 days. Theradiag SA is generating negative expected returns and assumes 6.4136% volatility on return distribution over the 90 days horizon. Simply put, 57% of stocks are less volatile than Theradiag, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Theradiag Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theradiag's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Theradiag SA, and traders can use it to determine the average amount a Theradiag's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0753
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALTHE |
Estimated Market Risk
| 6.41 actual daily | 57 57% of assets are less volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Theradiag is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theradiag by adding Theradiag to a well-diversified portfolio.
Theradiag Fundamentals Growth
Theradiag Stock prices reflect investors' perceptions of the future prospects and financial health of Theradiag, and Theradiag fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theradiag Stock performance.
| Return On Asset | -0.25 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 20.58 M | |||
| Shares Outstanding | 28.8 M | |||
| Price To Book | 10.04 X | |||
| Price To Sales | 34.41 X | |||
| Revenue | 1.48 M | |||
| EBITDA | (4.48 M) | |||
| Cash And Equivalents | 938.86 K | |||
| Cash Per Share | 0.11 X | |||
| Total Debt | 2.05 M | |||
| Debt To Equity | 909.10 % | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (3.88 M) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 10.83 M | |||
About Theradiag Performance
Assessing Theradiag's fundamental ratios provides investors with valuable insights into Theradiag's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Theradiag is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners. The company was founded in 2004 and is based in Malakoff, France. THERACLION operates under Medical Devices classification in France and is traded on Paris Stock Exchange. It employs 22 people.Things to note about Theradiag SA performance evaluation
Checking the ongoing alerts about Theradiag for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Theradiag SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theradiag SA generated a negative expected return over the last 90 days | |
| Theradiag SA has high historical volatility and very poor performance | |
| Theradiag SA has some characteristics of a very speculative penny stock | |
| Theradiag SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 1.48 M. Net Loss for the year was (3.76 M) with loss before overhead, payroll, taxes, and interest of (1.4 M). | |
| Theradiag SA has accumulated about 938.86 K in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11. | |
| Roughly 23.0% of the company shares are held by company insiders |
- Analyzing Theradiag's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theradiag's stock is overvalued or undervalued compared to its peers.
- Examining Theradiag's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theradiag's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theradiag's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Theradiag's stock. These opinions can provide insight into Theradiag's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Theradiag Stock Analysis
When running Theradiag's price analysis, check to measure Theradiag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theradiag is operating at the current time. Most of Theradiag's value examination focuses on studying past and present price action to predict the probability of Theradiag's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theradiag's price. Additionally, you may evaluate how the addition of Theradiag to your portfolios can decrease your overall portfolio volatility.